Lipid Rich Necrotic Core Lesion Detected by Cardiac Magnetic Resonance Imaging (CMR)
NCT ID: NCT01284270
Last Updated: 2013-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Adverse Plaque Characteristics by Coronary MR Angiography
NCT01986868
18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients
NCT07004673
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
NCT02265250
Right Ventricular Damage in Cardiovascular Magnetic Resonance
NCT01359306
Prospective Identification of High-risk Coronary Plaques Through Non-invasive Imaging
NCT02347306
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All Patients
All patients undergo the same study procedures
Cardiac MRI
Cardiac MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac MRI
Cardiac MRI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with known obstrucive coronary arterial disease for PCI in a native coronary artery
* Ability and willingness to consent and Authorization for use of personal health information (PHI)
* Ability and willingness to the required follow up procedures
Exclusion Criteria
* History of percutaneous coronary intervention in the major epicardial vessel of interest
* Lesion characteristics that preclude IVUS
* The presence of delayed enhancement in the territory of the study vessel on baseline CMR
* Patients with current history of cardiomyopathy which is known to cause enhancement on CMR study
* Patients who are considered hemodynamically unstable based on clinical assessment by the physician
* Patients with Class IV congestive heart failure at time of enrollment
* Patients with poorly controlled hypertension with SBP \>/= 210mmhg and/or DBP \>/=140 hypertension unable to be treated, at time of enrollment
* GFR\</=30 pre-procedure per institutional standards
* Patients with any known co-morbid conditions that is limiting their life expectancy to \< 1year
* A known contraindication to Adenosine, including but not limited to:
* Moderate to severe hyperactive airway disease such as asthma and severe COPD
* Second or third degree AV block
* Known sinus node disease, such as sick sinus syndrome or symptomatic bradycardia
* Known hypersensitivity to Adenosine
* A known contraindication to MRI
* Electronically, magnetically, and mechanically activated implants
* Ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, and cardiac pacemakers
* Metallic splinters/fragments in sensitive tissues including the eye, brain, spinal cord etc…
* Ferromagnetic haemostatic clips in the central nervous system
* A known contraindication to Gadolinium
* Patients with history of allergic reactions to gadolinium based contrast
* Patients with glomerular filtration rate (GFR) \</= 30ml/min
* Inability or unwillingness to consent and Authorization for use of PHI
* Patients who are unwilling or unable to follow up
* Known pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Volcano Corporation
INDUSTRY
GE Healthcare
INDUSTRY
Siemens Medical Solutions
INDUSTRY
Piedmont Healthcare
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Piedmont Heart Institute
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hawaii
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.